Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP
Background The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP). Methods The medical records...
Gespeichert in:
| Veröffentlicht in: | Mycoses 2021-01, Vol.64 (1), p.60-65 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 65 |
|---|---|
| container_issue | 1 |
| container_start_page | 60 |
| container_title | Mycoses |
| container_volume | 64 |
| creator | Lee, Ji Yun Kang, Minsu Suh, Koung Jin Kim, Ji‐Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Song, Kyoung‐Ho Kim, Eu Suk Kim, Hong Bin Lee, Keun‐Wook Kim, Jee Hyun Bang, Soo‐Mee Lee, Jong‐Seok Lee, Jeong‐Ok |
| description | Background
The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP).
Methods
The medical records of 739 DLBCL patients who received R‐CHOP between May 2004 and January 2019 were retrospectively evaluated. Patients were divided into two groups: those who received primary PCP prophylaxis (prophylaxis group) and those who did not (control group). The incidence rate of PCP in each group was calculated, and risk factors for PCP were evaluated in the control group.
Results
Baseline characteristics were significantly different between the two groups. Compared to the 602 patients who did not receive prophylaxis, the prophylaxis group (n = 137) had poor prognostic factors of older age, high lactate dehydrogenase (LDH) levels, advanced Ann Arbour stage, and high International Prognostic Index (IPI) risk scores. None of the patients receiving PCP prophylaxis developed PCP, while the incidence of PCP in the control group was 8.1% (definite cases 5.5% and probable cases 2.7%). Out of the 49 patients who developed PCP, 10 patients (20.4%) were admitted to the intensive care unit, and the PCP‐related death rate was 16.3% (8/49).
Conclusion
This study showed that PCP prophylaxis is highly effective against PCP infection and may help guide prevention of PCP during R‐CHOP treatment in DLBCL patients. |
| doi_str_mv | 10.1111/myc.13184 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2445969844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2469014673</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3304-5673d797c2f1196ebc27b44b48b0b2f17c44c321d5a8198e5a5ac67bc781b9683</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgCs7pwW8Q8KKHbkmTNs1Rhzph4hA97BTSNHUZ_WfSOnrzI_gZ_SRmqyfBXALv-0t4eAA4x2iC_ZmWvZpgghN6AEaYEh6gCLFDMEKckIBRxI7BiXMbhDDjYTwCq2Wlu7JWvWuNgxtj6w-tjIHNflwZCU0FM5PnndOwkPZNw5vvzy-liwIu-rJZ16WErdWy1RncmnYNn_16Nn9anoKjXBZOn_3eY_B6d_symweLp_uH2fUiUIQgGkQxIxnjTIU5xjzWqQpZSmlKkxSlfsYUpYqEOItkgnmiIxlJFbNUsQSnPE7IGFwO_za2fu-0a0Vp3C6frHTdORFSGvGYJ5R6evGHburOVj6dVzFHmPowXl0NStnaOatz0VhTStsLjMSuZOFLFvuSvZ0OdmsK3f8PxeNqNrz4AfWsfss</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2469014673</pqid></control><display><type>article</type><title>Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP</title><source>Access via Wiley Online Library</source><creator>Lee, Ji Yun ; Kang, Minsu ; Suh, Koung Jin ; Kim, Ji‐Won ; Kim, Se Hyun ; Kim, Jin Won ; Kim, Yu Jung ; Song, Kyoung‐Ho ; Kim, Eu Suk ; Kim, Hong Bin ; Lee, Keun‐Wook ; Kim, Jee Hyun ; Bang, Soo‐Mee ; Lee, Jong‐Seok ; Lee, Jeong‐Ok</creator><creatorcontrib>Lee, Ji Yun ; Kang, Minsu ; Suh, Koung Jin ; Kim, Ji‐Won ; Kim, Se Hyun ; Kim, Jin Won ; Kim, Yu Jung ; Song, Kyoung‐Ho ; Kim, Eu Suk ; Kim, Hong Bin ; Lee, Keun‐Wook ; Kim, Jee Hyun ; Bang, Soo‐Mee ; Lee, Jong‐Seok ; Lee, Jeong‐Ok</creatorcontrib><description>Background
The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP).
Methods
The medical records of 739 DLBCL patients who received R‐CHOP between May 2004 and January 2019 were retrospectively evaluated. Patients were divided into two groups: those who received primary PCP prophylaxis (prophylaxis group) and those who did not (control group). The incidence rate of PCP in each group was calculated, and risk factors for PCP were evaluated in the control group.
Results
Baseline characteristics were significantly different between the two groups. Compared to the 602 patients who did not receive prophylaxis, the prophylaxis group (n = 137) had poor prognostic factors of older age, high lactate dehydrogenase (LDH) levels, advanced Ann Arbour stage, and high International Prognostic Index (IPI) risk scores. None of the patients receiving PCP prophylaxis developed PCP, while the incidence of PCP in the control group was 8.1% (definite cases 5.5% and probable cases 2.7%). Out of the 49 patients who developed PCP, 10 patients (20.4%) were admitted to the intensive care unit, and the PCP‐related death rate was 16.3% (8/49).
Conclusion
This study showed that PCP prophylaxis is highly effective against PCP infection and may help guide prevention of PCP during R‐CHOP treatment in DLBCL patients.</description><identifier>ISSN: 0933-7407</identifier><identifier>EISSN: 1439-0507</identifier><identifier>DOI: 10.1111/myc.13184</identifier><language>eng</language><publisher>Berlin: Wiley Subscription Services, Inc</publisher><subject>B-cell lymphoma ; Cyclophosphamide ; Doxorubicin ; incidence ; L-Lactate dehydrogenase ; Lactic acid ; Lymphoma ; Medical records ; Monoclonal antibodies ; mortality ; Patients ; Pneumocystis pneumonia ; Pneumonia ; Prednisone ; Prophylaxis ; Risk factors ; Rituximab ; R‐CHOP ; Targeted cancer therapy ; trimethoprim‐sulfamethoxazole ; Vincristine</subject><ispartof>Mycoses, 2021-01, Vol.64 (1), p.60-65</ispartof><rights>2020 Wiley‐VCH GmbH</rights><rights>2021 Blackwell Verlag GmbH</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3304-5673d797c2f1196ebc27b44b48b0b2f17c44c321d5a8198e5a5ac67bc781b9683</citedby><cites>FETCH-LOGICAL-c3304-5673d797c2f1196ebc27b44b48b0b2f17c44c321d5a8198e5a5ac67bc781b9683</cites><orcidid>0000-0002-1881-8738 ; 0000-0002-5037-0523 ; 0000-0002-0938-3007 ; 0000-0001-9402-6372 ; 0000-0001-6426-9074 ; 0000-0002-4517-3840 ; 0000-0001-6262-372X ; 0000-0001-6491-2277 ; 0000-0001-7132-0157 ; 0000-0002-8491-703X ; 0000-0002-7336-7124 ; 0000-0002-1357-7015 ; 0000-0002-5835-7219 ; 0000-0003-1336-3620 ; 0000-0002-2292-906X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fmyc.13184$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fmyc.13184$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Lee, Ji Yun</creatorcontrib><creatorcontrib>Kang, Minsu</creatorcontrib><creatorcontrib>Suh, Koung Jin</creatorcontrib><creatorcontrib>Kim, Ji‐Won</creatorcontrib><creatorcontrib>Kim, Se Hyun</creatorcontrib><creatorcontrib>Kim, Jin Won</creatorcontrib><creatorcontrib>Kim, Yu Jung</creatorcontrib><creatorcontrib>Song, Kyoung‐Ho</creatorcontrib><creatorcontrib>Kim, Eu Suk</creatorcontrib><creatorcontrib>Kim, Hong Bin</creatorcontrib><creatorcontrib>Lee, Keun‐Wook</creatorcontrib><creatorcontrib>Kim, Jee Hyun</creatorcontrib><creatorcontrib>Bang, Soo‐Mee</creatorcontrib><creatorcontrib>Lee, Jong‐Seok</creatorcontrib><creatorcontrib>Lee, Jeong‐Ok</creatorcontrib><title>Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP</title><title>Mycoses</title><description>Background
The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP).
Methods
The medical records of 739 DLBCL patients who received R‐CHOP between May 2004 and January 2019 were retrospectively evaluated. Patients were divided into two groups: those who received primary PCP prophylaxis (prophylaxis group) and those who did not (control group). The incidence rate of PCP in each group was calculated, and risk factors for PCP were evaluated in the control group.
Results
Baseline characteristics were significantly different between the two groups. Compared to the 602 patients who did not receive prophylaxis, the prophylaxis group (n = 137) had poor prognostic factors of older age, high lactate dehydrogenase (LDH) levels, advanced Ann Arbour stage, and high International Prognostic Index (IPI) risk scores. None of the patients receiving PCP prophylaxis developed PCP, while the incidence of PCP in the control group was 8.1% (definite cases 5.5% and probable cases 2.7%). Out of the 49 patients who developed PCP, 10 patients (20.4%) were admitted to the intensive care unit, and the PCP‐related death rate was 16.3% (8/49).
Conclusion
This study showed that PCP prophylaxis is highly effective against PCP infection and may help guide prevention of PCP during R‐CHOP treatment in DLBCL patients.</description><subject>B-cell lymphoma</subject><subject>Cyclophosphamide</subject><subject>Doxorubicin</subject><subject>incidence</subject><subject>L-Lactate dehydrogenase</subject><subject>Lactic acid</subject><subject>Lymphoma</subject><subject>Medical records</subject><subject>Monoclonal antibodies</subject><subject>mortality</subject><subject>Patients</subject><subject>Pneumocystis pneumonia</subject><subject>Pneumonia</subject><subject>Prednisone</subject><subject>Prophylaxis</subject><subject>Risk factors</subject><subject>Rituximab</subject><subject>R‐CHOP</subject><subject>Targeted cancer therapy</subject><subject>trimethoprim‐sulfamethoxazole</subject><subject>Vincristine</subject><issn>0933-7407</issn><issn>1439-0507</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10E9LwzAYBvAgCs7pwW8Q8KKHbkmTNs1Rhzph4hA97BTSNHUZ_WfSOnrzI_gZ_SRmqyfBXALv-0t4eAA4x2iC_ZmWvZpgghN6AEaYEh6gCLFDMEKckIBRxI7BiXMbhDDjYTwCq2Wlu7JWvWuNgxtj6w-tjIHNflwZCU0FM5PnndOwkPZNw5vvzy-liwIu-rJZ16WErdWy1RncmnYNn_16Nn9anoKjXBZOn_3eY_B6d_symweLp_uH2fUiUIQgGkQxIxnjTIU5xjzWqQpZSmlKkxSlfsYUpYqEOItkgnmiIxlJFbNUsQSnPE7IGFwO_za2fu-0a0Vp3C6frHTdORFSGvGYJ5R6evGHburOVj6dVzFHmPowXl0NStnaOatz0VhTStsLjMSuZOFLFvuSvZ0OdmsK3f8PxeNqNrz4AfWsfss</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Lee, Ji Yun</creator><creator>Kang, Minsu</creator><creator>Suh, Koung Jin</creator><creator>Kim, Ji‐Won</creator><creator>Kim, Se Hyun</creator><creator>Kim, Jin Won</creator><creator>Kim, Yu Jung</creator><creator>Song, Kyoung‐Ho</creator><creator>Kim, Eu Suk</creator><creator>Kim, Hong Bin</creator><creator>Lee, Keun‐Wook</creator><creator>Kim, Jee Hyun</creator><creator>Bang, Soo‐Mee</creator><creator>Lee, Jong‐Seok</creator><creator>Lee, Jeong‐Ok</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1881-8738</orcidid><orcidid>https://orcid.org/0000-0002-5037-0523</orcidid><orcidid>https://orcid.org/0000-0002-0938-3007</orcidid><orcidid>https://orcid.org/0000-0001-9402-6372</orcidid><orcidid>https://orcid.org/0000-0001-6426-9074</orcidid><orcidid>https://orcid.org/0000-0002-4517-3840</orcidid><orcidid>https://orcid.org/0000-0001-6262-372X</orcidid><orcidid>https://orcid.org/0000-0001-6491-2277</orcidid><orcidid>https://orcid.org/0000-0001-7132-0157</orcidid><orcidid>https://orcid.org/0000-0002-8491-703X</orcidid><orcidid>https://orcid.org/0000-0002-7336-7124</orcidid><orcidid>https://orcid.org/0000-0002-1357-7015</orcidid><orcidid>https://orcid.org/0000-0002-5835-7219</orcidid><orcidid>https://orcid.org/0000-0003-1336-3620</orcidid><orcidid>https://orcid.org/0000-0002-2292-906X</orcidid></search><sort><creationdate>202101</creationdate><title>Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP</title><author>Lee, Ji Yun ; Kang, Minsu ; Suh, Koung Jin ; Kim, Ji‐Won ; Kim, Se Hyun ; Kim, Jin Won ; Kim, Yu Jung ; Song, Kyoung‐Ho ; Kim, Eu Suk ; Kim, Hong Bin ; Lee, Keun‐Wook ; Kim, Jee Hyun ; Bang, Soo‐Mee ; Lee, Jong‐Seok ; Lee, Jeong‐Ok</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3304-5673d797c2f1196ebc27b44b48b0b2f17c44c321d5a8198e5a5ac67bc781b9683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>B-cell lymphoma</topic><topic>Cyclophosphamide</topic><topic>Doxorubicin</topic><topic>incidence</topic><topic>L-Lactate dehydrogenase</topic><topic>Lactic acid</topic><topic>Lymphoma</topic><topic>Medical records</topic><topic>Monoclonal antibodies</topic><topic>mortality</topic><topic>Patients</topic><topic>Pneumocystis pneumonia</topic><topic>Pneumonia</topic><topic>Prednisone</topic><topic>Prophylaxis</topic><topic>Risk factors</topic><topic>Rituximab</topic><topic>R‐CHOP</topic><topic>Targeted cancer therapy</topic><topic>trimethoprim‐sulfamethoxazole</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Ji Yun</creatorcontrib><creatorcontrib>Kang, Minsu</creatorcontrib><creatorcontrib>Suh, Koung Jin</creatorcontrib><creatorcontrib>Kim, Ji‐Won</creatorcontrib><creatorcontrib>Kim, Se Hyun</creatorcontrib><creatorcontrib>Kim, Jin Won</creatorcontrib><creatorcontrib>Kim, Yu Jung</creatorcontrib><creatorcontrib>Song, Kyoung‐Ho</creatorcontrib><creatorcontrib>Kim, Eu Suk</creatorcontrib><creatorcontrib>Kim, Hong Bin</creatorcontrib><creatorcontrib>Lee, Keun‐Wook</creatorcontrib><creatorcontrib>Kim, Jee Hyun</creatorcontrib><creatorcontrib>Bang, Soo‐Mee</creatorcontrib><creatorcontrib>Lee, Jong‐Seok</creatorcontrib><creatorcontrib>Lee, Jeong‐Ok</creatorcontrib><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Mycoses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Ji Yun</au><au>Kang, Minsu</au><au>Suh, Koung Jin</au><au>Kim, Ji‐Won</au><au>Kim, Se Hyun</au><au>Kim, Jin Won</au><au>Kim, Yu Jung</au><au>Song, Kyoung‐Ho</au><au>Kim, Eu Suk</au><au>Kim, Hong Bin</au><au>Lee, Keun‐Wook</au><au>Kim, Jee Hyun</au><au>Bang, Soo‐Mee</au><au>Lee, Jong‐Seok</au><au>Lee, Jeong‐Ok</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP</atitle><jtitle>Mycoses</jtitle><date>2021-01</date><risdate>2021</risdate><volume>64</volume><issue>1</issue><spage>60</spage><epage>65</epage><pages>60-65</pages><issn>0933-7407</issn><eissn>1439-0507</eissn><abstract>Background
The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B‐cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP).
Methods
The medical records of 739 DLBCL patients who received R‐CHOP between May 2004 and January 2019 were retrospectively evaluated. Patients were divided into two groups: those who received primary PCP prophylaxis (prophylaxis group) and those who did not (control group). The incidence rate of PCP in each group was calculated, and risk factors for PCP were evaluated in the control group.
Results
Baseline characteristics were significantly different between the two groups. Compared to the 602 patients who did not receive prophylaxis, the prophylaxis group (n = 137) had poor prognostic factors of older age, high lactate dehydrogenase (LDH) levels, advanced Ann Arbour stage, and high International Prognostic Index (IPI) risk scores. None of the patients receiving PCP prophylaxis developed PCP, while the incidence of PCP in the control group was 8.1% (definite cases 5.5% and probable cases 2.7%). Out of the 49 patients who developed PCP, 10 patients (20.4%) were admitted to the intensive care unit, and the PCP‐related death rate was 16.3% (8/49).
Conclusion
This study showed that PCP prophylaxis is highly effective against PCP infection and may help guide prevention of PCP during R‐CHOP treatment in DLBCL patients.</abstract><cop>Berlin</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/myc.13184</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1881-8738</orcidid><orcidid>https://orcid.org/0000-0002-5037-0523</orcidid><orcidid>https://orcid.org/0000-0002-0938-3007</orcidid><orcidid>https://orcid.org/0000-0001-9402-6372</orcidid><orcidid>https://orcid.org/0000-0001-6426-9074</orcidid><orcidid>https://orcid.org/0000-0002-4517-3840</orcidid><orcidid>https://orcid.org/0000-0001-6262-372X</orcidid><orcidid>https://orcid.org/0000-0001-6491-2277</orcidid><orcidid>https://orcid.org/0000-0001-7132-0157</orcidid><orcidid>https://orcid.org/0000-0002-8491-703X</orcidid><orcidid>https://orcid.org/0000-0002-7336-7124</orcidid><orcidid>https://orcid.org/0000-0002-1357-7015</orcidid><orcidid>https://orcid.org/0000-0002-5835-7219</orcidid><orcidid>https://orcid.org/0000-0003-1336-3620</orcidid><orcidid>https://orcid.org/0000-0002-2292-906X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0933-7407 |
| ispartof | Mycoses, 2021-01, Vol.64 (1), p.60-65 |
| issn | 0933-7407 1439-0507 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2445969844 |
| source | Access via Wiley Online Library |
| subjects | B-cell lymphoma Cyclophosphamide Doxorubicin incidence L-Lactate dehydrogenase Lactic acid Lymphoma Medical records Monoclonal antibodies mortality Patients Pneumocystis pneumonia Pneumonia Prednisone Prophylaxis Risk factors Rituximab R‐CHOP Targeted cancer therapy trimethoprim‐sulfamethoxazole Vincristine |
| title | Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A37%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pneumocystis%20jirovecii%20pneumonia%20in%20diffuse%20large%20B%E2%80%90cell%20Lymphoma%20treated%20with%20R%E2%80%90CHOP&rft.jtitle=Mycoses&rft.au=Lee,%20Ji%20Yun&rft.date=2021-01&rft.volume=64&rft.issue=1&rft.spage=60&rft.epage=65&rft.pages=60-65&rft.issn=0933-7407&rft.eissn=1439-0507&rft_id=info:doi/10.1111/myc.13184&rft_dat=%3Cproquest_cross%3E2469014673%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2469014673&rft_id=info:pmid/&rfr_iscdi=true |